TODAY LETTER DATED
|
|
|
- Prosper Atkins
- 5 years ago
- Views:
Transcription
1 TODAY LETTER DATED GLOBAL CLINICAL TRIAL SR. NO. COMPANY NAME REFERENCE NO. STATUS 1 M/S. RESEARCH ASSOCIATES INDIA PVT PA APPROVAL LETTER LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY NO. STATUS 1. M/S KUSUM HEALTHCARE PVT.., AHMEDABAD C/O M/S AMANTA HEALTHCARE., TAL: MATAR, DIST: KHEDA , GUJARAT 2. M/S ALEMBIC LIMITED, VADODARA C/O M/S. DENIS CHEM LAB, TAL: KALOL (N.G.), DISTRICT GANDHINAGAR- (GUJARAT) 3. M/S ALEMBIC LIMITED, VADODARA C/O M/S AMANTA HEALTHCARE., VILLAGE: HARIYALA, TAL: MATAR, DIST: KHEDA, GUJARAT 4. M/S TABLETS (INDIA) LIMITED, NO. 179, T.H. ROAD, CHENNAI M/S SUN PHARMACEUTICAL INDUSTRIES, HALOL- BARODA HIGHWAY, HALOL, , DIST. PANCHMAHAL, GUJARAT 6. M/S. UNIQUE PHARMACEUTICAL LABORATORIES, PLOT NO. IV, G.I.D.C, INDUSTRIAL ESTATE, PANOLI , DISTRICT-BHARUCH, GUJARAT 7. M/S TIL HEALTHCARE PRIVATE., EGMORE, CHENNAI C/O M/S TABLETS INDIA., 179, T.H. ROAD, CHENNAI QUERY QUERY QUERY APPROVAL APPROVAL APPROVAL APPROVAL
2 SUBSEQUENT NEW DRUG S. NO. NAME OF THE FIRM REFERENCE NO. FTS NO. TYPE OF LETTER 1. M/S AMI LIFE SCIENCE APPROVAL LETTER 2. M/S NOVARTIS APPROVAL LETTER HEALTHCARE 3. M/S SUN PHARMA BE NOC, TEST LICENSE 4. DR. REDDY S APPROVAL LETTER LABORATORIES 5. M/S SYNOKEM BE NOC, DEFICIENCY LETTER, IPC NOC 6. M/S BAL PHARMA APPROVAL LETTER 7. M/S SMAI LABS DEFICIENCY LETTER 8. M/S SHILPA DEFICIENCY LETTER THERAPEUTICS 9. M/S MICRO LABS DEFICIENCY LETTER 10. M/S PANACEA DEFICIENCY LETTER, IPC NOC 11. M/S INTAS APPROVAL LETTER FDC DIVISION S.NO. NAME OF COMPANY DIARY NO. DOCUMENT 1. M/S. PSYCHOTROPICS INDIA LETTER 2. M/S. MASCOT HEALTH SERIES 15940/14576/14570/15936/1 13 LETTERS 4569/17373/15938/15937/17 367/17374/15935/17369/ M/S. SMAYAN HEALTHCARE 12783/12782/12379/ LETTERS 4. M/S. STEDMAN NIL LETTER
3 5. M/S. INNOVA CAPTAB LETTER 6. M/S. TRECS PHARMA LETTER 7. M/S. GOLDENCROSS PHARMA 9170 LETTER 8. M/S. GKM NEW PHARMA 31683/31678/ LETTERS 9. M/S. SUN PHARMA 3172/21782 LETTER/CT NOC 10. M/S. AKUMS DRUGS LETTER 11. M/S. EAST INDIA 1310 LETTER 12. M/S. SMILAX HEALTHCARE LETTER 13. M/S. RAVENBHEL HEALTHCARE LETTER 14. M/S. ARISTO 32876/24139/14640 APPROVAL LETTER/LETTER 15. M/S. BLUE CROSS LABORATORIES 4747 LETTER INTERNATIONAL CELL S. NO NAME OF FIRM TYPE 1. M/S ALEMBIC PHAMRACEUTICALS, GUJARAT 2. M/S AMOLI ORGANICS PVT, VADODARA 3. M/S ANDHRA MEDI PHARMA INDIA PVT, ANDHRA PRADESH 4. M/S DECCAN NUTRACEUTICALS PVT, PUNE 5. M/S GLENMARK GENERICS, DAHEJ 6. M/S MEDINEX LABORATORIES PVT, BHAVNAGAR 7. M/S LUPIN, VADODARA 8. M/S LUPIN, VADODARA LETTER LETTER
4 9. M/S SOLARA ACTIVE PHARMA SCIECES, CUDDALORE 10. M/S UNICHEM LABORATORIES, DHAR, M.P LETTER NEW DRUG S.NO. NAME OF APPLICANT DIARY NO. TYPE OF LETTER 1. M/S. SANOFI-SYNTHELABO (I) PVT - IPC NOC 2. M/S. HETERO LABS - PERMISSION 3. M/S. HONOUR LAB - PERMISSION 4. M/S. ASTELLAS PHARMA INDIA PVT - TL 5. M/S. IMAGING PRODUCT (I) PVT - PERMISSION 6. M/S. VIRBAC ANIMAL HEALTH - PERMISSION, AMENDMENT PHARMA INDIA PVT 7. M/S. MYLAN LABORATORIES - PERMISSION 8. M/S. MEDILUX LABORATORIES PVT - QUERY LETTER 9. M/S. CADILA HEALTHCARE - LETTER 10. M/S. MSN ORGANICS PVT - AMENDMENT 11. M/S. NATCO PHARMA - LETTER MEDICAL DEVICE DIVISION S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. ADVANCE LIFE SCIENCES PVT.., LETTER 2. M/S. DISPOSAFE HEALTH & LIFE CARE., LETTER THE STATE DRUGS CONTROLLER, PANCHKULA THE DEPUTY DRUGS CONTROLLER, GHAZIABAD
5 3. M/S. DCL DENCARE INDIA PVT.., (CLAA) LETTER THE STATE DRUGS CONTROLLER, PANCHKULA THE DEPUTY DRUGS CONTROLLER, GHAZIABAD DIAGNOSTIC DIVISION S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. CYTOCARE TECHNOLOGIES PVT.., NIL LETTER BIOLOGICAL DIVISION S. NO. NAME OF FIRM REFERENCE NO. TYPE OF LETTER 1 M/S WOCKHARDT 2797, APPROVAL LETTER 2 M/S LG LIFE SCIENCE APPROVAL LETTER 3 M/S APAC BIOTECH CLARIFICATION LETTER 4 M/S SERUM INSTITUTE OF APPROVAL LETTER INDIA 5 M/S HLL LIFE CARE 5446 APPROVAL LETTER 6 M/S BIOCON LIMITED 20309, ORDER, APPROVAL LETTER 7 M/S SANOFI PASTEUR INDIA 21596,17458,31941,2820 APPROVAL LETTER 8 M/S INTAS 18181,20917 APPROVAL LETTER 9 M/S LUPIN APPROVAL LETTER 10 M/S RELIANCE LIFE SCIENCE 15864,10938 APPROVAL LETTER 11 M/S ELI LILLY AND COMPANY 7663 APPROVAL LETTER 12 M/S ROCHE PRODUCTS INDIA APPROVAL LETTER 13 M/S GSK SMITH KLINE ORDER
6 14 M/S BHARAT BIOTECH 15932, CLARIFICATION LETTER, CDL LETTER 15 M/S MSD PHARMACEUTICAL CLARIFICATION LETTER 16 M/S CADILA HEALTHCARE CLARIFICATION LETTER 17 M/S VENKATESHWARA HATCHERIES PVT 8601 CLARIFICATION LETTER 18 M/S BAYER CLARIFICATION LETTER PVT 19 M/S PLASMAGEN BIOSCIENCE APPROVAL LETTER PVT 20 M/S SHANTHA BIOTECHNICS INSPECTION LETTER 21 M/S VAXILIA PVT 21225,21224 APPROVAL LETTER 22 M/S BOEHRINGER INGELHEIM INDIA 16608,16609, 14047, APPROVAL LETTER
LETTERS FOR ISSUE ON
S FOR ISSUE ON 01.09.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1. M/S TYCHE INDUSTRIES LTD., ANDHRA PRADESH, INDIA IMPORT S. NAME OF APPLICANT DIARY TYPE OF 1. PIRAMAL ENTERPRISES LTD. 25471 APPROVAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 21.06.2016 LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY NO. STATUS 01 M/S. GLOBAL PHARMA HEALTHCARE PVT. LTD., THIRUPORUR 27509 APPROVAL BIOLOGICAL DIVISION NAME OF COMPANY DY.NO. STATUS
LETTERS FOR ISSUE ON
S FOR ISSUE ON 15.10.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1 M/S NATCO PHARMA LIMITED HYDERABAD MEDICAL DEVICE S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. GENETIX BIOTECH ASIA PVT. LTD. 22073 APPROVAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 11.04.2017 BIOLOGICAL DIVISION NAME OF COMPANY DY. NO. STATUS M/S ZUVENTUS HEALTHCARE LTD 6981 APPROVAL M/S TECHINVENTION LIFE SCIENCES 1208 CLARIFICATION M/S CADILA PHARMACEUTICALS LTD
LETTERS FOR ISSUE ON
S FOR ISSUE ON 14.03.2016 IMPORT S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. TABLETS (INDIA) LIMITED 5973 APPROVAL 2. TABLETS (INDIA) LIMITED 5974 APPROVAL 3. CLARIS OTSUKA PRIVATE LIMITED 7373 APPROVAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 25.04.2017 BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ALEMBIC PHARMACEUTICALS 2. M/S. ALEMBIC PHARMACEUTICALS 3. M/S. ALEMBIC PHARMACEUTICALS 4. M/S. EMCURE PHARMACEUTICALS
LETTERS FOR ISSUE ON
S FOR ISSUE ON 04.10.2017 MEDICAL DEVICE DIVISION S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. ABBOTT MEDICAL OPTICS PVT. LTD., 14608 QUERY 2. M/S. ABBOTT MEDICAL OPTICS PVT. LTD., 14609 QUERY 3. DR. ULHAS
LETTERS FOR ISSUE ON
S FOR ISSUE ON 04.12.2015 NEW DRUG S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. M/S. VIRCHOW BIOTECH PVT LTD - QUERY 2. M/S. MSN LABORATORIES PVT - CT-NOC & BE NOC LTD (3) 3. M/S. NATCO PHARMA LTD. - BE-NOC
LETTERS FOR ISSUE ON
S FOR ISSUE ON 14.12.2015 LVP DIVISION S. COMPANY NAME FTS /DIARY STATUS 01 M/S. AXA PARENTERALS LTD., ROORKEE 60262 APPROVAL 02 M/S. UNIJULES LIFE SCIENCES LTD., NAGPUR 61147 APPROVAL 03 M/S. INNVOL MEDICAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 29.11.2016 COSMETICS DIVISION S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. M/S. WELLA INDIA PVT. LTD., MUMBAI 29233, 29524 & 28513 APPROVAL 2. M/S. PROCTER & GAMBLE HOME PRODUCTS PVT. LTD.,
LETTERS FOR ISSUE ON
S FOR ISSUE ON 19.06.2015 BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ACCUTEST RESEARCH LABORATORIES (I) PVT., NAVI MUMBAI-400 709 2. M/S. ACCUTEST RESEARCH LABORATORIES (I) PVT.,
LETTERS FOR ISSUE ON
S FOR ISSUE ON 03.09.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1. M/S LUPIN TARAPUR, MAHARASHTRA & WC 2. M/S JPN PHARMA PVT. PALGHAR, MAHARASHTRA WC 3. M/S OPTIMUS DRUGS A.P. WC VACCINE DIVISION S.
LETTERS FOR ISSUE ON
S FOR ISSUE ON 05.10.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE OF DOCUMENT 1. M/S. ARRIGO INTERNATIONAL,INDORE 2 M/S. EUROLIFE HEALTHCARE PVT. LTD. HARIDWAR NEW DRUG S. NAME OF APPLICANT DIARY TYPE
LETTERS FOR ISSUE ON
S FOR ISSUE ON 27.08.2015 NEW DRUG S. NAME OF APPLICANT DIARY TYPE OF 1. M/S. INTAS PHARMACEUTICALS LIMITED - CT NOC (2) 2. M/S. PFIZER LIMITED - QUERY 3. M/S. MSN LABORATORIES - ADDITIONAL SITE 4. M/S.
LETTERS FOR ISSUE ON
S FOR ISSUE ON 17.07.2015 NEW DRUG S.NO. NAME OF APPLICANT DIARY TYPE OF NO. 1. M/S. CIREX PHARMACEUTICALS LTD - QUERY 2. M/S. LUPIN LIMITED - ADDITIONAL SITES REGISTRATION S.NO. NAME OF APPLICANT DIARY
LETTERS FOR ISSUE ON
S FOR ISSUE ON 17.05.2016 BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ACCUTEST RESEARCH MUMBAI-400709 2. M/S. ACCUTEST RESEARCH MUMBAI-400709 3. M/S. ACCUTEST RESEARCH MUMBAI-400709
LETTERS FOR ISSUE ON
LETTERS FOR ISSUE ON 27.12.2017 LVP DIVISION S. NO. COMPANY NAME FTS NO. /Diary No. STATUS 01 M/s. Akums Drugs & Pharmaceuticals, Haridwar 02 M/s. Unique Pharmaceutical Laboratories,Guj. (License No.4)
Subject: Consolidated list of all cases of price fixation of new drugs received from various companies under para 5 of DPCO 2013
Subject: Consolidated list of all cases of price fixation of new drugs received from various companies under para 5 of DPCO 2013 Sl. No. F.No. Name of the Company/ Formulation Date of receipt of application
RESULTS AND DISCUSSION
RESULTS AND DISCUSSION 203 4.1 General Introduction: The researcher has collected both the primary and secondary data. The primary data is collected by direct interaction by using formal questionnaire
Case 3:15-cv PGS-TJB Document 1 Filed 08/04/15 Page 1 of 111 PageID: 1 ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) )
Case 3:15-cv-05982-PGS-TJB Document 1 Filed 08/04/15 Page 1 of 111 PageID: 1 Liza M. Walsh Christine I. Gannon CONNELL FOLEY LLP One Newark Center 1085 Raymond Boulevard, 19th Floor Newark, New Jersey
File no./drug Name Name of firm/ Institute Recommendations. New Drugs Division
Recommendations: I approve the minutes of 52 nd SEC (Oncology & hematology) held on 13.04.2017 at CDSCO HQ New Delhi and recommended the following: Agenda 1 12-63/16-DC Ferric Pyrophosphate citrate solution
Status of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 01/03/2016 to 29/04/2016
1. M/s LG Life Sciences India Pvt. Ltd.,Basement Commercial SCO No. 321, Sector-29, Gurgaon, India 2. M/s Eli Lilly and Co (I) Pvt. Ltd., Bldg. No. 14, Gala No. 1 to 4, 1 st Fl, Arihant Comm. Complex,
New Delhi, the 18 th December, 2017 ORDER
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of National Pharmaceutical Pricing Authority
BRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
1 Agio Pharmaceuticals Limited 15/31/2013-EP(Engg) dt:21.11.2013 7,98,217.00 2 Akriti Pharmaceuticals Pvt Ltd 15/31/2013-EP(Engg) dt:21.11.2013 15,10,268.00 3 Akriti Pharmaceuticals Pvt Ltd 15/31/2013-EP(Engg)
Central Inspection Plan Using Risk Based Approach Of Vaccine Manufacturing Units for 2017
, follow-up, failure A NORTH ZONE 1 M/s Biomed Pvt. Ltd, C-96, Site I, Bulandshahar Road, Ind. Area, Ghaziabad. 1. Oral Polio Vaccine IP, 2. Vi Typhoid Vaccine (Bio Typh TM ) IP, 3. Haemophilus Type-B
ORDER. Table. (1) (2) (3) (4) (5) (6) 1. Glimepiride Metformin Tablet
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of National Pharmaceutical Pricing Authority
Minimumum Price (Rs.) 3.30 Maximum Price (Rs.) 4.57 Average of all considered (Rs.) 3.73 Retail Price (Rs.) 4.33
Computataion of Retail Price based on Jan.-2016 Data under Para 4 of DPCO 2013 Cholecalciferol 800 IU Drops of M/s Raptakos, Brett & Co.Ltd. Number of Companies cosisting of Market Share of 1% & Above
3. Dr.Rajutitus Chacko, Prof. & Head, Dept. of Medical Oncology, CMC, Vellore.
MINUTES OF THE 6 th MEETING OF TECHNICAL COMMITTEE HELD ON 25-07-2013 UNDER CHAIRMANSHIP OF DGHS FOR SUPERVISING CLINICAL TRIALS ON NEW CHEMICAL ENTITIES IN THE LIGHT OF DIRECTIONS OF THE HON BLE SUPREME
ORDER. Table. Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Teneligliptin Hydrobromide + Metformin HCL (SR) Tablet
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of s National Pricing Authority ORDER New
Status of Registration Certificate (Form 41) of Human Vaccines issued from 01/03/2015 to 29/05/2015. Human vaccines
Status of Registration Certificate (Form 41) of Human Vaccines issued from 01/03/2015 to 29/05/2015 S. No. Firm Name of Formulation Registration Certificate No. & Validity 1. M/s. Nirlac Chemicals,14 th
Education. Current Activities
Nirali Mehta, M.Sc., M.Phil. Founder & Consultant Biostatistician Ahmedabad, Gujarat, India. M +91 9377060504 E nirali.mehta@pharma-stats.in W www.pharma-stats.in Education 1998-2001 Bachelor of Science
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
Recommendation:- The 19 th SEC - (Oncology & Hematology) deliberated the proposals on and recommended the following:-
Recommendation:- The 19 th SEC - (Oncology & Hematology) deliberated the proposals on 05.11.2014 and recommended the following:- Agend a No. File No. 1. File No.: 12-75/13-DC Afatinib film coated tablet
Case 1:14-cv LPS Document 195 Filed 01/05/16 Page 1 of 5 PageID #: 6023
Case 1:14-cv-00121-LPS Document 195 Filed 01/05/16 Page 1 of 5 PageID #: 6023 IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE FOREST LABO RA TORIES, INC., FOREST LABO RA TORIES HOLDINGS,
M/s. Hetero Labs Ltd.
:- The 1 st SEC (Gastroenterology&Hepatology) meeting deliberated the proposals on 06.01.2017 and recommended the following:- Agenda New Drugs Division Proposal 1 12-54/16-DC Sofosbuvir and Velpatasvir
Medicines availability short-term supply issues Last updated 01/05/18
Short-term supply issues This resource includes availability information on medicines that are reported to have supply issues, with next expected availability within the next three months. This list is
Case 2:09-cv DMC-CCC Document 1 Filed 03/20/2009 Page 1 of 95. Of Counsel:
Case 2:09-cv-01302-DMC-CCC Document 1 Filed 03/20/2009 Page 1 of 95 Charles M. Lizza William C. Baton SAUL EWING LLP One Riverfront Plaza Newark, NJ 07102 (973) 286-6700 clizza@saul.com Attorneys for Plaintiff
TRADE MARKS REGISTRY AHMEDABAD
TRADE MARKS REGISTRY AHMEDABAD OPPOSITION HEARING LIST FOR THE MONTH OF JUNE-2016 DATE OF HEARING 13.06.2016 1. 934855/05 Opp. AMD-245342 M/s. Ajanta Pharma Limited, Mumbai / Mr. Manoj G. Menda, Mumbai
ORDER. Table. Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Rosuvastatin + Clopidogrel Capsule (Crevast CV 20)
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceutical
WHO PUBLIC INSPECTION REPORT (WHOPIR) Contract Research Organization
SOP 408.4 Annex C 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int Part 1: General information WHO PUBLIC INSPECTION REPORT (WHOPIR) Contract
Status of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 30/04/2016 to 20/12/2016
Status of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 30/04/2016 to 20/12/2016 RECOMBINANT PRODUCTS S. No. Firm Name of Formulation Import License No. &
TABLE 7 ADVANTAGES AND DISADVANTAGES OF TOXOID VACCINES SUBUNIT VACCINES Applications of Subunit Vaccines TABLE 8 APPLICATIONS OF
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 19 Apr 2019 13:49:20 GMT) CTRI Number CTRI/2009/091/000126 [Registered on: 15/04/2009] - Last Modified On 03/09/2014 Post Graduate Thesis Type of Trial
REGULATORY UPDATES: APPROVAL, DENIALS AND AGREEMENTS REGULATORY UPDATES: APPROVAL, (CONTINUED)... 38
CHAPTER ONE: INTRODUCTION... 1 STUDY OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 INTENDED AUDIENCE... 2 SCOPE OF THE STUDY... 2 METHODOLOGY... 2 INFORMATION SOURCES... 2 ABOUT THE AUTHOR... 3 RELATED
Dataset : PharmaTrac MAT MAY PharmaTrac Overview MAY 18
PharmaTrac Overview MAY 18 8434 8956 9655 10422 8112 8917 9549 8258 8921 9406 8668 9630 9381 8662 8373 8999 9013 9796 10413 8742 9315 10050 8458 9180 8601 9092 9767 8364 9145 10583 10173 10387 10217 10476
Name of firm/applicant
Recommendation:- The 18 th Subject Expert Committee (Oncology & Hematology) deliberated the proposals on 04.07.2014 and recommended the following:- Agenda no. Drug name Name of firm/applicant Recommendations
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 02 Sep 2018 23:38:24 GMT) CTRI Number Last Modified On 05/02/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Thu, 18 Oct 2018 14:39:26 GMT) CTRI Number Last Modified On 06/04/2018 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
14 th SEC- Gastroenterology& Hepatology held on at CDSCO (HQ), FDA Bhawan, Kotla road, NewDelhi
14 th SEC- Gastroenterology& Hepatology held on 27-08-2015 at CDSCO (HQ), FDA Bhawan, Kotla road, NewDelhi 110 002 Recommendation:- The 14 th SEC ( Gastroenterology& Hepatology) meeting deliberated the
What s New
What s New 23.12.2016 NPPA has fixed/revised ceiling prices of 55 scheduled formulations of Schedule-I under Drugs ( Control) Amendment Order,2016 and Retail of 29 formulations under DPCO, 2013 in related
NPPA has fixed/revised ceiling prices/retail prices of 22 formulations under Drugs (Prices Control) Order,
What s New 12.06.2018 NPPA has fixed/revised ceiling prices/retail prices of 22 formulations under Drugs (Prices Control) Order, 2013 NPPA has fixed/revised ceiling prices/retail prices of 22 formulations
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 07 Oct 2018 22:54:26 GMT) CTRI Number Last Modified On 11/05/2018 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
Companies Database, Mobile Database, Id Database, Credit
m All India Database We Provides Database Companies Database, Mobile Database, Email Id Database, Credit Card Holder Database, Corporate database, CEO s Database, Corporate Employee Database, Car s Owner
REF/2014/04/ CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Wed, 02 May 2018 19:38:55 GMT) CTRI Number Last Modified On 13/12/2014 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
Homoeopathy Colleges
HOMOEOPATHIC COLLEGE PRMISSION STATUS FOR THE YEAR 2018-19 SR NO COLLEGES / INSTITUTES COLLEGE TYPE CODE PERMISSION STATUS INTAKE TOTAL GQ MQ NRI 1 GOVERNMENT HOMEOPATHIC MEDICAL COLLEGE AND HOSPITAL,
Information for Vermont Prescribers of Prescription Drugs Long Form Fetzima (levomilnacipran) Extended Release Capsules
Information for Vermont Prescribers of Prescription Drugs Long Form Fetzima (levomilnacipran) Extended Release Capsules The prices listed below are Average Wholesale Prices ( AWP ) as established and made
Name of firm/applicant. Torrent Pharmaceuticals. Glenmark Pharmaceuticals. M/s. Torrent Pharmaceutical. Torrent Pharmaceuticals
Recommendation:- The 14 Th SEC (Cardiovascular & Renal) deliberated the proposals on 21.08.2014 and recommended the following:- Agenda no. File no Name of firm/applicant Recommendations 1. 04-228/06-D(pt
GTU INNOVATION COUNCIL
Report of GTU Innovation Council, Himmatnagar Sankul 1. A Meeting with industries, GIDC, Modasa As an initiative step, an interaction meeting with industry people was held at GIDC, Modasa, by untiring
Vascular Endothelial Growth Factor Inhibitor Market
May 2017 Report Id : REP-GB-3292 Status : Ongoing Category : Healthcare, Pharmaceuticals & Medical Devices 2015 Future Market Insights, All Rights Reserved About Future Market Insights Future Market Insights
AGENDA PAPERS FOR THE EIGHTEENTH MEETING SUB-COMMITTEE ON LARGE ANIMALS (SCLA)
AGENDA PAPERS FOR THE EIGHTEENTH MEETING OF SUB-COMMITTEE ON LARGE ANIMALS (SCLA) DATE : 18.04.2005 TIME : 3 : 00 P.M. VENUE : 8 TH FLOOR, JEEVAN PRAKASH BUILDING, 25, KASTURBA GANDHI MARG, NEW DELHI.
Recommendations of thesec (Dermatology & Allergy) made in its 23 rd meeting held on at CDSCO HQ New Delhi: New Drugs Division
Recommetions of thesec (Dermatology & Allergy) made in its 23 rd meeting held on 11.05.2017 at CDSCO HQ New Delhi: File /Drug Name Recommetions New Drugs Division 1 12-28/15-DC (Pt-B) Apremilast 10/20/30
List Of Antihepatitis Pharmaceutical Products (included to support Global Fund Policy for Co-Infections and Co-Morbidities)
Edition: Version 11-19th of July 2018 List of A & B Products List Of Antihepatitis Pharmaceutical Products (included to support Global Fund Policy for Co-Infections and Co-Morbidities) As from the version
10 th SEC- (Reproductive & Urology)meetingheld on at CDSCO (HQ), FDA Bhawan, Kotla road, New Delhi PROGRAMME SCHEDULE
10 th SEC- (Reproductive & Urology)meetingheld on 16-01-2015 at CDSCO (HQ), FDA Bhawan, Kotla road, New Delhi 110 002 PROGRAMME SCHEDULE Recommendation:- The 10 th SEC (Reproductive and Urology) meeting
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Thu, 18 Oct 2018 01:14:31 GMT) CTRI Number Last Modified On 06/06/2017 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division)
Directorate General of Health Services Office of Drugs Controller General (India) (Biological Division) List of r-dna drug products approved in the country (Form 45 and 45A) from 1 st Jan 2015 to 30 th
Global Aspergillosis Drugs Market Professional Survey Report 2016
Report Information More information from: https://www.wiseguyreports.com/reports/526011 Global Aspergillosis Drugs Market Professional Survey Report 2016 Report / Search Code: WGR526011 Publish Date: 24
Vaccine Industry in India An Emerging Global Hub
Vaccine Industry in India An Emerging Global Hub Authors: Dr. Banu Priya C, Pugazhenthi. E, Shreyas Rajan, Dr. Neelam Malhotra, Mallikarjun bidari Global Outlook Asia is emerging as the vaccine hub of
New Drugs Division. Frequently Asked Questions (FAQs) on Approval of new Phytopharmaceutical Drugs
Central Drugs Standard Control Organization Directorate General of Health Services Ministry of Health and Family Welfare Government of India New Drugs Division Frequently Asked Questions (FAQs) on Approval
Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo
ORDER. Table. Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Rosuvastatin Clopidogrel Tablet
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceutical
Vaccine Technologies and Global Markets
A BCC Research Pharmaceutical Report and Global Markets PHM014D Use this report to: Learn about the strengths and weaknesses of each category of human and veterinary vaccine to prevent or treat infectious
Oncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
US pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
Information for Vermont Prescribers of Prescription Drugs Long Form
Information for Vermont Prescribers of Prescription Drugs Long Form Pylera (bismuth subcitrate potassium, metronidazole, and tetracycline hydrochloride) Capsules The prices listed below are Average Wholesale
TOTAL MAT 1,52,81, % Unit PTR (Rs.) MAT (Rs.) SKU wise MAT % प क व रण Pack Description छ प BRAND. क पन Company. S. No. Unique No.
Number of Companies consisting of Market Share of 1% & Above 2 3.1 Adrenaline Injection 1 mg/ml Per ml Sum of MAT value considered for price calculation (in Lakhs) 152.69 Sum of PTR per unit considered
MEDICATION GUIDE. Aripiprazole Tablets (AR-i-PIP-ra-zole)
MEDICATION GUIDE Aripiprazole Tablets (AR-i-PIP-ra-zole) What is the most important information I should know about aripiprazole tablets? (For other side effects, also see What are the possible side effects
BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS
BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS BIO022G August 2015 Kim Lawson Project Analyst ISBN: 1-62296-134-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023
Global Psoriasis Pipeline Drugs Market Assessment: Industry Analysis, Pipeline Review, Clinical Trials, Market Potential Forecast to 2023 Global Psoriasis Pipeline Drugs Industry Sizing, Growth and Forecast
John Ansell President, John Ansell Consultancy Thame, UK
Rutgers University Monday 29 September 2014 Co Eli Lilly Bristol-Myers Squibb Novo Nordisk Pfizer GlaxoSmithKline Takeda Sanofi Novartis AstraZeneca Roche Otsuka Johnson & Johnson Otsuka Abbott Teva 1
Dr. Shweta Kumarswami MDS (Prosthodontist)
Dr. Shweta Kumarswami MDS (Prosthodontist) 2B Medicare Centre, Near M. J. Library, Ahmedabad, 380006, Gujarat, India. Mobile: +919825014461. Clinic: +9179-26578446 E-mail: info@drshwetakumarswami.com Website:
Information for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs LIPITOR (atorvastatin calcium) tablets This list does not imply that the products on this chart are interchangeable or have the same efficacy or
Table 1 Details of products supplied and the correlation coefficient of each of these products against its reference.
Table 1 Details of products supplied and the correlation coefficient of each of these products against its reference. Product Number API Test product Dose/ mg Manufacturer Country of manufacture Country
REF/2016/08/ CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 26 v 2017 06:12:26 GMT) CTRI Number Last Modified On 08/08/2017 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study Scientific
Rapid Life Drugs & Healthcare
+91-8048948845 Rapid Life Drugs & Healthcare https://www.rapidlife.net/ We are amongst the leading manufacture, traders, distributors and suppliers of this impeccable and diverse range of Pharmaceutical
How and Why Vaccines Are Developed by Industry. Stanley A. Plotkin
How and Why Vaccines Are Developed by Industry Stanley A. Plotkin Merieux 2012 1 Why Vaccines are Different than Drugs 1) Given to healthy people, high safety required 2) Larger governmental role 3) Low
CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 MARKET ANALYSES AND FORECASTS... 2 INTENDED AUDIENCE... 2 INFORMATION SOURCES... 2 ANALYST
PROVISIONAL RATE LIST FOR NIT 120 (Pharma)
all 1 120003 Acenocoumarol/Nicoumalone Tablet 2 mg 10 x 10 15,000 L1 CIRON DRUGS AND PHARMACEUTICALS PVT LTD 259.0004 259.0004 L2 ABBOTT HEALTHCARE PRIVATE LIMITED 386.66 405.993 2 Adrenochrome Monosemicarbazone
Kenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3
American Academy of Dermatology 75 th Annual Meeting, Orlando, FL; March 3 7, 2017 Poster 4563 Novel Evaluation of Psoriasis Area and Severity Index (PASI) Data: Distribution of PASI Improvements in a
TRADE MARKS REGISTRY AHMEDABAD
TRADE MARKS REGISTRY AHMEDABAD OPPOSITION HEARING LIST FOR THE MONTH OF SPTEMBER-2013 DATE OF HEARING 10.09.2013 R. T. M. 1. 842945/16 Rect. AMD-249059 Mr. Pankajbhai Sitaram Nayak, Hearing on Section
Indian Red Cross Society Gujarat State Branch
Indian Red Cross Society Gujarat State Branch Thalassemia & Sickle Cell Prevention Programme th School going students of standard 8 of covering Districts Ahmedabad, Anand, Jamnagar, Kutch, Rajkot, Vadodara,
Clinical impact of practice registers in Bourgogne and Rhône Alpes
Clinical impact of practice registers in Bourgogne and Rhône Alpes Dr Yannick Béjot The Dijon Stroke Registry EA4184, University Hospital and Medical School of Dijon, France Dr Carlos El KHOURY c.elkhoury@ch-vienne.fr
Regulatory Reforms-Future of Plasma Protein Therapy in India
Regulatory Reforms-Future of Plasma Protein Therapy in India Ranjeet S. Ajmani PlasmaGen BioSciences Pvt. Ltd. Bangalore, India PPB-2013 Price Tag of Contrast q Uniqueness q Co-existence : Rich & Poor
NATIONAL DRUG REGISTER OF UGANDA HERBAL HUMAN FEBRUARY 2018
NATIONAL DRUG REGISTER OF UGANDA HERBAL HUMAN FEBRUARY 2018 LICENSE No NDA/MAL/HHP/80 94 LICENSE HOLDER BHARGAVA PHYTOLAB PVT. LTD LOCAL TECHNICAL REPRESENTATIVE PRODUCT NAME AND BRAND POSTORAL GAMA SILYBIN
Edmund Healthcare Pvt. Ltd.
+91-8048410921 Edmund Healthcare Pvt. Ltd. https://www.edmundhealthcare.in/ Our firm is ranked as the leading Trader and Supplier of a wide array of Pharmaceutical Injection, Pharmaceutical Tablets, Pharmaceutical
(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
Admission Committee for Professional Under Graduate Medical Courses (ACPUGMEC) :
Admission Committee for Professional Under Graduate Medical Courses (ACPUGMEC) : 2017-18 First - Last Position of Candidates :: NEET - (ROUND - 07) - PARTICIPATING CANDIDATES B.A.M.S. GOVT. AKHANDANAND
The Crisis in. Vaccine Development
The Crisis in Vaccine Development Stanley A. Plotkin 1 Annecy 2015 The Evolution of the Vaccine Industry 1. 18 th -19 th Centuries Pioneers 2. 1900-1950 National Producers 3. 1960-1980 Globalization 4.
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sat, 09 Mar 2019 16:29:06 GMT) CTRI Number CTRI/2010/091/000679 [Registered on: 23/08/2010] - Last Modified On 10/07/2015 Post Graduate Thesis Type of Trial
Creating Lasting Value
Creating Lasting Value Investor Presentation April 2017 NSE:SUNPHARMA BSE:524715 Bloomberg:SUNP IN Reuters:SUN.BO WWW.SUNPHARMA.COM Disclaimer Except for the historical information contained herein, statements